EQL Pharma

CEO Axel Schörling comments: "The listing on Nasdaq Main Market gives us a quality stamp and is a natural step in EQL Pharma's growth story. Our current annual revenue growth rate is around 40%, and we aim to continue to be a fast-growing company for many years to come. Through the Nasdaq listing, we also gain access to international capital markets and institutional investors can become shareholders of EQL to a greater extent than before."

EQL Pharma's share will be traded in the Small Cap segment and will retain both its ticker (EQL) and ISIN code (SE0005497732). In connection with the list change, there will be no offering or issue of new shares and shareholders of EQL Pharma will not need to take any actions.

The Company has, in connection with the list change, prepared a prospectus, which is available on the Company's website, www.eqlpharma.com.

Advisors

Setterwalls Advokatbyrå AB is acting as legal advisor to EQL Pharma in connection with the listing.